Results 8,021-8,040 of 21,431 for speaker:Alan Kelly
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Alan Kelly: My point is this is beyond a stakeholder.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Alan Kelly: This is an area to which we might return. The issue of genetics is very interesting.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Alan Kelly: Have we a copy of this? None of us has a copy of this.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Alan Kelly: I do not want to hold up the meeting but I just wanted to ensure I was not the only person who has not seen it.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Alan Kelly: It is obvious that we need an extensive national medicines policy to be driven at departmental level. It is to be hoped that will happen in the next Government. Mr. Judge stated that the Minister cannot get involved in drug reimbursement decisions. If that is so, what happened in the case of Orkambi? Did the Minister become involved contrary to the Act referred to by Mr. Judge or did he...
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Alan Kelly: That is what happened with Orkambi.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Alan Kelly: That is so in one case I am aware of.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Alan Kelly: About what percentage?
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Alan Kelly: To save time, because this is very statistics-orientated, I might supply a list and the witnesses might come back to me. Would that be okay?
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Alan Kelly: That is what I am asking about.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Alan Kelly: I know that.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Alan Kelly: That needs to be looked at.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Alan Kelly: I am not leaving here until we get an answer to my last question. What Mr. Hennessy has just said is of no comfort. This is going to explode in everyone's face. The witnesses all know what I am talking about. One cannot discriminate between two people on the basis that one got cancer at one point and another got cancer a year later. There was a crisis in this country and the Government...
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Alan Kelly: I know the whole process. It takes a couple of years but all of that was skipped in this instance.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Alan Kelly: I understand that and I agree that it will be across Europe. In terms of the women affected, it will work for some but not for others. I am not saying that this is a miracle drug in any way, shape or form but it seems to be helping Vicky Phelan, with whom I am in contact a lot. In other cases, it may not help but all of these women will do anything they can, regardless of whether they are...
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Alan Kelly: I thank Professor Barry for his honesty.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Alan Kelly: I appreciate the Professor's honesty.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Alan Kelly: That did not happen in this case.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Alan Kelly: I am aware of that and Dr. Fennelly and Professor Crown have written about it. I understand that it can be done off-licence. The issue here is that it costs €8,500 every three weeks and the State is paying for it. I invite Mr. Judge to respond.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Alan Kelly: I am interested in Mr. Judge's view on that specific point.